WHO Global Consultation on Haemovigilance
Place: Dubai, United Arab Emirates
Date: 20-22 November 2012
Haemovigilance is a continuous process of data collection and analysis of transfusion-related adverse events and reactions (AR/AE) in order to investigate their causes and outcomes, and prevent their occurrence or recurrence. A haemovigilance system is an integral part of quality management in a blood system and is required for the continual improvement of the quality and safety of blood products and the transfusion process. Haemovigilance is essential to identify and prevent the occurrence or recurrence of adverse reactions and unwanted events, and to increase the safety, efficacy and efficiency of blood transfusion. It covers all activities of the blood chain, vein-to-vein, from donor to recipient.
The WHO Blood Transfusion Safety programme in the Department for Health Systems Policies and Workforce, WHO headquarters (WHO/BTS), convened the Global Consultation on Haemovigilance in Dubai, United Arab Emirates on 20-22 November 2012. This consultation was jointly organized by WHO-HQ/Geneva, Sharjah Blood Transfusion and Research Center and the Government of the United Arab Emirates, in collaboration with the International Haemovigilance Network and the International Society of Blood Transfusion. This three-day Global Consultation on Haemovigilance brought together participants from developing and developed countries, including those with established systems and those with plans to start haemovigilance. A total of 150 participants from 46 countries attended the consultation representing all regions of WHO. The participants included senior policy makers from ministries of health, and representatives from key institutions, agencies and stakeholders in establishing haemovigilance systems - at national, regional or hospital level, e.g. blood services, public health institutions, hospitals, regulatory agencies and professional bodies.